Oncogenic co-operation in beta-cell tumorigenesis.

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Pancreatic islet neoplasms, including insulinomas, are rare endocrine tumors with poorly understood genetic drivers.
• While hereditary multiple endocrine neoplasia type 1 (MEN1) involves menin deficiency, sporadic insulinomas often lack obvious genetic alterations.
• Proto-oncogenes like c-myc are implicated in beta-cell growth and tumorigenesis, with activation appearing early in human insulinoma progression.

Purpose of the Study:

• To investigate the role of deregulated Myc expression in adult pancreatic beta-cells in vivo.
• To explore the molecular and genetic events underlying insulinoma initiation and progression using transgenic mouse models.
• To determine the necessity of apoptosis suppression for Myc-driven beta-cell survival and neoplasia.

Main Methods:

• Development of transgenic mouse models with regulated ectopic Myc expression in beta-cells.
• Investigation of beta-cell proliferation, apoptosis, and islet morphology following Myc activation.
• Co-expression of Bcl-x(L) to inhibit Myc-induced apoptosis and assess its impact on tumor development.

Main Results:

• Ectopic Myc activation in beta-cells initially induced both proliferation and apoptosis, with apoptosis predominating, leading to islet involution and diabetes.
• Inhibition of Myc-induced apoptosis via Bcl-x(L) co-expression resulted in significantly enlarged, hypervascularized, hyperplastic, and invasive islets.
• These findings highlight the critical role of apoptosis suppression in the survival of Myc-activated beta-cells.

Conclusions:

• Early suppression of apoptosis is essential for the survival of Myc-activated pancreatic beta-cells.
• This suppression is a key event enabling the development of islet neoplasia.
• Targeting apoptosis pathways may offer novel therapeutic strategies for insulinoma.